Literature DB >> 23375284

Renal transplantation between siblings with unrecognized Fabry disease.

S Taneda1, K Honda, I Nakajima, S Huchinoue, H Oda.   

Abstract

Fabry disease is an X-linked lysosomal storage disease caused by deficiency of the lysosomal hydrolase, α-galactosidase A (α-Gal A). We report a case of a renal transplant recipient with unrecognized Fabry disease who received the allograft from a sibling donor with unrecognized Fabry disease. The recipient began to show a gradual increase of the serum creatinine with mild proteinuria at 3 years after transplantation. Histopathologic examination revealed finely vacuolated podocytes, demonstrated by ultrastructural examination to contain osmophilic myelin bodies. Furthermore, the recipient showed reduced circulating levels of α-Gal A and elevated urinary levels of globotriaosylceramide. These findings indicated that both the recipient and the donor suffered from Fabry disease of the renal variant phenotype. Enzyme replacement therapy (ERT) was initiated in the recipient, which resulted in a slight decrease of serum creatinine. Although mild proteinuria persisted, initiation of ERT in the recipient led to improvement of the renal function.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375284     DOI: 10.1016/j.transproceed.2012.10.024

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Whole-Exome Sequencing Enables a Precision Medicine Approach for Kidney Transplant Recipients.

Authors:  Nina Mann; Daniela A Braun; Kassaundra Amann; Weizhen Tan; Shirlee Shril; Dervla M Connaughton; Makiko Nakayama; Ronen Schneider; Thomas M Kitzler; Amelie T van der Ven; Jing Chen; Hadas Ityel; Asaf Vivante; Amar J Majmundar; Ankana Daga; Jillian K Warejko; Svjetlana Lovric; Shazia Ashraf; Tilman Jobst-Schwan; Eugen Widmeier; Hannah Hugo; Shrikant M Mane; Leslie Spaneas; Michael J G Somers; Michael A Ferguson; Avram Z Traum; Deborah R Stein; Michelle A Baum; Ghaleb H Daouk; Richard P Lifton; Shannon Manzi; Khashayar Vakili; Heung Bae Kim; Nancy M Rodig; Friedhelm Hildebrandt
Journal:  J Am Soc Nephrol       Date:  2019-01-17       Impact factor: 10.121

2.  Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

Authors:  Hiroki Maruyama; Kaori Miyata; Mariko Mikame; Atsumi Taguchi; Chu Guili; Masaru Shimura; Kei Murayama; Takeshi Inoue; Saori Yamamoto; Koichiro Sugimura; Koichi Tamita; Toshihiro Kawasaki; Jun Kajihara; Akifumi Onishi; Hitoshi Sugiyama; Teiko Sakai; Ichijiro Murata; Takamasa Oda; Shigeru Toyoda; Kenichiro Hanawa; Takeo Fujimura; Shigehisa Ura; Mimiko Matsumura; Hideki Takano; Satoshi Yamashita; Gaku Matsukura; Ryushi Tazawa; Tsuyoshi Shiga; Mio Ebato; Hiroshi Satoh; Satoshi Ishii
Journal:  Genet Med       Date:  2018-03-15       Impact factor: 8.822

3.  Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.

Authors:  Yumi Aoyama; Yusuke Ushio; Takashi Yokoyama; Sekiko Taneda; Shiho Makabe; Miki Nishida; Shun Manabe; Masayo Sato; Hiroshi Kataoka; Ken Tsuchiya; Kosaku Nitta; Toshio Mochizuki
Journal:  Intern Med       Date:  2020-04-01       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.